Omeros Corporation (NASDAQ:OMER) announced that an abstract highlighting positive results from the ongoing OMS721 Phase 2 clinical trial in patients with hematopoietic stem …
Omeros Corporation (NASDAQ:OMER) announced that following physician request it will provide continued supply of OMS721 for a pediatric patient with hematopoietic stem cell …
Omeros Corporation (NASDAQ:OMER) announced the successful outcome of its recently completed post-marketing clinical trial of the effect of OMIDRIA (phenylephrine and ketorolac injection) 1%/0.3% …
As both earnings and election season are coming to a close, analysts are chiming in with varied expectations for three biotech players: Valeant …
Omeros Corporation (NASDAQ:OMER) announced recent highlights and developments as well as financial results for the third quarter of 2016, which include: 3Q 2016 total …
Omeros Corporation (NASDAQ:OMER) announced that it has completed the initial funding under its senior secured credit facility with affiliates ofCRG LP, a healthcare-focused …
Omeros Corporation (NASDAQ:OMER) announced that it has filed an application for orphan drug designation with the U.S.
Omeros Corporation (NASDAQ:OMER) announced positive results from a Phase 2 clinical trial evaluating the effects of a peroxisome proliferator-activated receptor (PPAR)-gamma agonist in heroin-dependent …
Omeros Corporation (NASDAQ:OMER) announced that it has requested fast track designation from the U.S.
Omeros Corporation (NASDAQ:OMER) announced positive results in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) from the company’s Phase 2 clinical trial of …
